Synonymous substitution rates predict HIV disease progression as a result of underlying replication dynamics

PLoS Computational Biology

Volumn 3, Issue 2, 2007, Pages 0282-0292

  Lemey, Philippe ^a   Kosakovsky Pond, Sergei L ^b   Drummond, Alexei J ^c   Pybus, Oliver G ^a   Shapiro, Beth ^a   Barroso, Helena ^d,e   Taveira, Nuno ^d,e   Rambaut, Andrew ^f  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF AUCKLAND   (New Zealand)

^d RESEARCH INSTITUTE FOR MEDICINES IMED ULISBOA   (Portugal)

^e INSTITUTO SUPERIOR DE CIÊNCIAS DA SAÚDE EGAS MONIZ   (Portugal)

^f UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMICAL ACTIVATION; CHROMOSOMES; CLOCKS; DISEASES; PHYLOGENETIC;

CO-INFECTIONS; DISEASE FREE; DISEASE PROGRESSION; GENERATION TIME; HIV TRANSMISSION; HOST IMMUNE RESPONSE; IMMUNE ACTIVATION; PHYLOGENETICS; SUBSTITUTION RATES; SYNONYMOUS SUBSTITUTIONS;

IMMUNE SYSTEM;

ARTICLE; DISEASE ASSOCIATION; DISEASE COURSE; ENVELOPE GENE; GENETIC ASSOCIATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; IMMUNE SYSTEM; MOLECULAR CLOCK; MOLECULAR EVOLUTION; NUCLEOTIDE SEQUENCE; PATHOGENICITY; PHYLOGENY; VIRUS REPLICATION; AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; BIOLOGICAL MODEL; CODON; COMPUTER SIMULATION; GENETIC PREDISPOSITION; GENETIC VARIABILITY; GENETICS; METHODOLOGY; MOLECULAR GENETICS; VIRUS ACTIVATION;

HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2;

VIRUS ENVELOPE PROTEIN;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; CODON; COMPUTER SIMULATION; DISEASE PROGRESSION; DNA MUTATIONAL ANALYSIS; EVOLUTION, MOLECULAR; GENETIC PREDISPOSITION TO DISEASE; GENETIC VARIATION; HIV INFECTIONS; HUMANS; MODELS, GENETIC; MOLECULAR SEQUENCE DATA; VIRAL ENVELOPE PROTEINS; VIRUS ACTIVATION; VIRUS REPLICATION;

EID: 33847246314     PISSN: 1553734X     EISSN: 15537358     Source Type: Journal    
DOI: 10.1371/journal.pcbi.0030029     Document Type: Article

References (71)

1. Richman DD, Wrin T, Little SJ, Petropoulos CJ (2003) Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc Natl Acad Sci U S A 100: 4144-4149.
2. Frost SD, Wrin T, Smith DM, Kosakovsky Pond SL, Liu Y, et al. (2005) Neutralizing antibody responses drive the evolution of human immunodeficiency virus type 1 envelope during recent HIV infection. Proc Natl Acad Sci U S A 102: 18514-18519.
3. Cecilia D, Kleeberger C, Munoz A, Giorgi JV, Zolla-Pazner S (1999) A longitudinal study of neutralizing antibodies and disease progression in HIV-1-infected subjects. J Infect Dis 179: 1365-1374.
4. Koup RA, Safrit JT, Cao Y, Andrews CA, McLeod G, et al. (1994) Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol 68: 4650-4655.
5. Carrington M, Nelson GW, Martin MP, Kissner T, Vlahov D, et al. (1999) HLA and HIV-1: Heterozygote advantage and B*35-Cw*04 disadvantage. Science 283: 1748-1752.
6. Trachtenberg E, Korber B, Sollars C, Kepler TB, Hraber PT, et al. (2003) Advantage of rare HLA supertype in HIV disease progression. Nat Med 9: 928-935.
7. Asquith B, Edwards CT, Lipsitch M, McLean AR (2006) Inefficient cytotoxic T lymphocyte-mediated killing of HIV-1-infected cells in vivo. PLoS Biol 4: e90.
8. Addo MM, Yu XG, Rathod A, Cohen D, Eldridge RL, et al. (2003) Comprehensive epitope analysis of human immunodeficiency virus type 1 (HIV-1)-specific T-cell responses directed against the entire expressed HIV-1 genome demonstrate broadly directed responses, but no correlation to viral load. J Virol 77: 2081-2092.
9. Cao J, McNevin J, Holte S, Fink L, Corey L, et al. (2003) Comprehensive analysis of human immunodeficiency virus type 1 (HIV-1)-specific gamma interferon-secreting CD8+ T cells in primary HIV-1 infection. J Virol 77: 6867-6878.
10. Lichterfeld M, Yu XG, Cohen D, Addo MM, Malenfant J, et al. (2004) HIV-1 nef is preferentially recognized by CD8 T cells in primary HIV-1 infection despite a relatively high degree of genetic diversity. AIDS 18: 1383-1392.
11. Goulder PJ, Watkins DI (2004) HIV and SIV CTL escape: Implications for vaccine design. Nat Rev Immunol 4: 630-640.
12. Martinez-Picado J, Prado JG, Fry EE, Pfafferott K, Leslie A, et al. (2006) Fitness cost of escape mutations in p24 gag in association with control of human immunodeficiency virus type 1. J Virol 80: 3617-3623.
13. Leslie AJ, Pfafferott KJ, Chetty P, Draenert R, Addo MM, et al. (2004) HIV evolution: CTL escape mutation and reversion after transmission. Nat Med 10: 282-289.
14. Shankarappa R, Margolick JB, Gange SJ, Rodrigo AG, Upchurch D, et al. (1999) Consistent viral evolutionary changes associated with the progression of human immunodeficiency virus type 1 infection. J Virol 73: 10489-10502.
15. Ganeshan S, Dickover RE, Korber BT, Bryson YJ, Wolinsky SM (1997) Human immunodeficiency virus type 1 genetic evolution in children with different rates of development of disease. J Virol 71: 663-677.
16. Strunnikova N, Ray SC, Livingston RA, Rubalcaba E, Viscidi RP (1995) Convergent evolution within the V3 loop domain of human immunodeficiency virus type 1 in association with disease progression. J Virol 69: 7548-7558.
17. Williamson S (2003) Adaptation in the env gene of HIV-1 and evolutionary theories of disease progression. Mol Biol Evol 20: 1318-1325.
18. Ross HA, Rodrigo AG (2002) Immune-mediated positive selection drives human immunodeficiency virus type 1 molecular variation and predicts disease duration. J Virol 76: 11715-11720.
19. Grossman Z, Meier-Schellersheim M, Paul WE, Picker LJ (2006) Pathogenesis of HIV infection: What the virus spares is as important as what it destroys. Nat Med 12: 289-295.
20. Giorgi JV, Hultin LE, McKeating JA, Johnson TD, Owens B, et al. (1999) Shorter survival in advanced human immunodeficiency virus type 1 infection is more closely associated with T lymphocyte activation than with plasma virus burden or virus chemokine coreceptor usage. J Infect Dis 179: 859-870.
21. Sousa AE, Carneiro J, Meier-Schellersheim M, Grossman Z, Victorino RM (2002) CD4 T cell depletion is linked directly to immune activation in the pathogenesis of HIV-1 and HIV-2 but only indirectly to the viral load. J Immunol 169: 3400-3406.
22. Seo TK, Kishino H, Thorne JL (2004) Estimating absolute rates of synonymous and nonsynonymous nucleotide substitution in order to characterize natural selection and date species divergences. Mol Biol Evol 21: 1201-1213.
23. Silvestri G, Feinberg MB (2003) Turnover of lymphocytes and conceptual paradigms in HIV infection. J Clin Invest 112: 821-824.
24. Kelly JK (1996) Replication rate and evolution in the human immunodeficiency virus. J Theor Biol 180: 359-364.
25. Kelly JK, Williamson S, Orive ME, Smith MS, Holt RD (2003) Linking dynamical and population genetic models of persistent viral infection. Am Nat 162: 14-28.
26. Drummond AJ, Ho SYW, Phillips MJ, Rambaut A (2006) Relaxed phylogenetics and dating with confidence. PLoS Biol 4: e88.
27. Shriner D, Shankarappa R, Jensen MA, Nickle DC, Mittler JE, et al. (2004) Influence of random genetic drift on human immunodeficiency virus type 1 env evolution during chronic infection. Genetics 166: 1155-1164.
28. Edwards CTT, Holmes EC, Pybus OG, Wilson DJ, Viscidi RP, et al. (2006) Evolution of the human immunodeficiency virus envelope gene is dominated by negative selection. Genetics 174: 1441-1453.
29. Kosakovsky Pond SL, Frost SD, Grossman Z, Gravenor M, Richman DD, et al. (2006) Adaptation to different human populations by HIV-1 revealed by codon-based analysis. PloS Comput Biol 2 (6): e62.
30. Kosakovsky Pond SL, Muse SV (2005) Site-to-site variation of synonymous substitution rates. Mol Biol Evol 22: 2375-2385.
31. Frost SD, Dumaurier MJ, Wain-Hobson S, Brown AJ (2001) Genetic drift and within-host metapopulation dynamics of HIV-1 infection. Proc Natl Acad Sci U S A 98: 6975-6980.
32. Williamson S, Perry SM, Bustamante CD, Orive ME, Stearns MN, et al. (2005) A statistical characterization of consistent patterns of human immunodeficiency virus evolution within infected patients. Mol Biol Evol 22: 456-468.
33. Janssens W, Nkengasong J, Heyndrickx L, Van der Auwera G, Vereecken K, et al. (1999) Intrapatient variability of HIV type 1 group O ANT70 during a 10-year follow-up. AIDS Res Hum Retroviruses 15: 1325-1332.
34. O'Donovan D, Ariyoshi K, Milligan P, Ota M, Yamuah L, et al. (2000) Maternal plasma viral RNA levels determine marked differences in motherto-child transmission rates of HIV-1 and HIV-2 in The Gambia. MRC/Gambia Government/University College London Medical School working group on mother-child transmission of HIV. AIDS 14: 441-448.
35. Marlink R, Kanki P, Thior I, Travers K, Eisen G, et al. (1994) Reduced rate of disease development after HIV-2 infection as compared to HIV-1. Science 265: 1587-1590.
36. Chaix-Baudier ML, Chappey C, Burgard M, Letourneur F, Igual J, et al. (1998) First case of mother-to-infant HIV type 1 group O transmission and evolution of C2V3 sequences in the infected child. French HIV Pediatric Cohort Study Group. AIDS Res Hum Retroviruses 14: 15-23.
37. Barroso H, Araujo F, Gomes MH, Mota-Miranda A, Taveira N (2004) Phylogenetic demonstration of two cases of perinatal human immunodeficiency virus type 2 infection diagnosed in adulthood. AIDS Res Hum Retroviruses 20: 1373-1376.
38. Choisy M, Woelk CH, Guegan JF, Robertson DL (2004) Comparative study of adaptive molecular evolution in different human immunodeficiency virus groups and subtypes. J Virol 78: 1962-1970.
39. Sanjuan R, Moya A, Elena SF (2004) The distribution of fitness effects caused by single-nucleotide substitutions in an RNA virus. Proc Natl Acad Sci U S A 101: 8396-8401.
40. Lawn SD, Butera ST, Folks TM (2001) Contribution of immune activation to the pathogenesis and transmission of human immunodeficiency virus type 1 infection. Clin Microbiol Rev 14: 753-777.
41. Bukrinsky MI, Stanwick TL, Dempsey MP, Stevenson M (1991) Quiescent T lymphocytes as an inducible virus reservoir in HIV-1 infection. Science 254: 423-427.
42. Dimitrov DS, Willey RL, Sato H, Chang LJ, Blumenthal R, et al. (1993) Quantitation of human immunodeficiency virus type 1 infection kinetics. J Virol 67: 2182-2190.
43. Hosmalin A, Samri A, Dumaurier MJ, Dudoit Y, Oksenhendler E, et al. (2001) HIV-specific effector cytotoxic T lymphocytes and HIV-producing cells colocalize in white pulps and germinal centers from infected patients. Blood 97: 2695-2701.
44. Finzi D, Plaeger SF, Dieffenbach CW (2006) Defective virus drives human immunodeficiency virus infection, persistence, and pathogenesis. Clin Vaccine Immunol 13: 715-721.
45. Schindler M, Munch J, Kutsch O, Li H, Santiago ML, et al. (2006) Nef-mediated suppression of T cell activation was lost in a lentiviral lineage that gave rise to HIV-1. Cell 125: 1055-1067.
46. Deacon NJ, Tsykin A, Solomon A, Smith K, Ludford-Menting M, et al. (1995) Genomic structure of an attenuated quasi species of HIV-1 from a blood transfusion donor and recipients. Science 270: 988-991.
47. Kirchhoff F, Greenough TC, Brettler DB, Sullivan JL, Desrosiers RC (1995) Brief report: Absence of intact nef sequences in a long-term survivor with nonprogressive HIV-1 infection. N Engl J Med 332: 228-232.
48. Blaak H, van der Ende ME, Boers PH, Schuitemaker H, Osterhaus AD (2006) In vitro replication capacity of HIV-2 variants from long-term aviremic individuals. Virology 353: 144-154.
49. Nowak M, May RM (2000) Virus dynamics. New York: Oxford University Press. 250 p.
50. Ljunggren K, Moschese V, Broliden PA, Giaquinto C, Quinti I, et al. (1990) Antibodies mediating cellular cytotoxicity and neutralization correlate with a better clinical stage in children born to human immunodeficiency virus-infected mothers. J Infect Dis 161: 198-202.
51. Bonhoeffer S, Holmes EC, Nowak MA (1995) Causes of HIV diversity. Nature 376: 125.
52. Bailey JR, Lassen KG, Yang HC, Quinn TC, Ray SC, et al. (2006) Neutralizing antibodies do not mediate suppression of human immunodeficiency virus type 1 in elite suppressors or selection of plasma virus variants in patients on highly active antiretroviral therapy. J Virol 80: 4758-4770.
53. Grenfell BT, Pybus OG, Gog JR, Wood JL, Daly JM, et al. (2004) Unifying the epidemiological and evolutionary dynamics of pathogens. Science 303: 327-332.
54. Shriner D, Rodrigo AG, Nickle DC, Mullins JI (2004) Pervasive genomic recombination of HIV-1 in vivo. Genetics 167: 1573-1583.
55. Anisimova M, Nielsen R, Yang Z (2003) Effect of recombination on the accuracy of the likelihood method for detecting positive selection at amino acid sites. Genetics 164: 1229-1236.
56. Kosakovsky Pond SL, Frost SD (2005) A simple hierarchical approach to modeling distributions of substitution rates. Mol Biol Evol 22: 223-234.
57. Yang Z (1998) Likelihood ratio tests for detecting positive selection and application to primate lysozyme evolution. Mol Biol Evol 15: 568-573.
58. Kosakovsky Pond SL, Muse SV (2004) HyPhy: Hypothesis testing using phylogenies. In: Nielsen R, editor. Statistical methods in molecular evolution. New York: Springer. pp. 125-182
59. Rambaut A (2000) Estimating the rate of molecular evolution: Incorporating non-contemporaneous sequences into maximum likelihood phylogenies. Bioinformatics 16: 395-399.
60. Drummond AJ, Nicholls GK, Rodrigo AG, Solomon W (2002) Estimating mutation parameters, population history and genealogy simultaneously from temporally spaced sequence data. Genetics 161: 1307-1320.
61. Drummond A, Rambaut A (2003) BEAST version 1.3 [computer program]. Available: http://evolve.zoo.ox.ac.uk/beast. Accessed 18 January 2007.
62. Drummond AJ, Rambaut A, Shapiro B, Pybus OG (2005) Bayesian coalescent inference of past population dynamics from molecular sequences. Mol Biol Evol 22: 1185-1192.
63. Rambaut A, Drummond AJ (2003) Tracer, version 1.2 [computer program]. Available: http://evolve.zoo.ox.ac.uk/software.html. Accessed 21 January 2007.
64. Kosakovsky Pond SL, Frost SD (2005) Not so different after all: A comparison of methods for detecting amino-acid sites under selection. Mol Biol Evol 22: 1208-1222.
65. Kosakovsky Pond SL, Frost SD, Muse SV (2005) HyPhy: Hypothesis testing using phylogenies. Bioinformatics 21: 676-679.
66. Esteves A, Piedade J, Santos C, Venenno T, Canas-Ferreira WF, et al. (2001) Follow-up study of intrahost HIV type 2 variability reveals discontinuous evolution of C2V3 sequences. AIDS Res Hum Retroviruses 17: 253-256.
67. Gottlieb GS, Mullins JI (2001) Re: Follow-up study of intrahost HIV type 2 variability reveals discontinuous evolution of C2V3 sequences. AIDS Res Hum Retroviruses 17: 1563-1565.
68. Shi Y, Brandin E, Vincic E, Jansson M, Blaxhult A, et al. (2005) Evolution of human immunodeficiency virus type 2 coreceptor usage, autologous neutralization, envelope sequence and glycosylation. J Gen Virol 86: 3385-3396.
69. Nielsen R, Yang Z (1998) Likelihood models for detecting positively selected amino acid sites and applications to the HIV-1 envelope gene. Genetics 148: 929-936.
70. McVean G, Awadalla P, Fearnhead P (2002) A coalescent-based method for detecting and estimating recombination from gene sequences. Genetics 160: 1231-1241.
71. Carvajal-Rodriguez A, Crandall KA, Posada D (2006) Recombination estimation under complex evolutionary models with the coalescent composite-likelihood method. Mol Biol Evol 23: 817-827.